MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
2023; Mary Ann Liebert, Inc.; Linguagem: Inglês
10.1089/thy.2023.0240
ISSN1557-9077
AutoresSophie Leboulleux, D. Benisvy, David Taïeb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadège Anizan, Aurélie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, Isabelle Borget,
Tópico(s)Adrenal and Paraganglionic Tumors
ResumoThyroidVol. 33, No. 9 Research LettersMERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid CancerSophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadege Anizan, Aurelie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, and Isabelle BorgetSophie LeboulleuxAddress correspondence to: Sophie Leboulleux, MD, PhD, Department of Endocrinology, Diabetology,, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Rue Gabrielle Perret Gentil, 4, Geneve 1205, Switzerland E-mail Address: [email protected]Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.Department of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Hôpitaux Universitaires de Genève, Geneve, Switzerland.Search for more papers by this author, Daniele BenisvyDepartment of Nuclear Medicine, CLCC Antoine Lacassagne, Nice, France.Search for more papers by this author, David TaiebDepartment of Nuclear Medicine, CHU de La Timone, Marseille, France.Search for more papers by this author, Marie AttardDepartment of Imaging Gustave Roussy and University Paris Saclay, Villejuif, France.Search for more papers by this author, Claire BournaudDepartment of Nuclear Medicine, Hospices Civils de Lyon, Lyon, France.Search for more papers by this author, Marie Terroir-Cassou-MounatDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.Department of Nuclear Medicine UICT Oncopole, CLCC Institut Claudius Regaud, Toulouse, France.Search for more papers by this author, Ludovic LacroixDepartment of Medical Biology and Pathology, Gustave Roussy and University Paris Saclay, Villejuif, France.AMMICa UAR3655/US23, Gustave Roussy, Villejuif, France.Search for more papers by this author, Nadege Anizanhttps://orcid.org/0000-0002-8021-1515Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.Department of Physics, Gustave Roussy and University Paris Saclay, Villejuif, France.Search for more papers by this author, Aurelie SchiazzaDepartment of Nuclear Medicine, CLCC Antoine Lacassagne, Nice, France.Search for more papers by this author, Marie Eve GarciaDepartment of Oncology, CHU de La Timone, Marseille, France.Search for more papers by this author, Abir Al GhuzlanDepartment of Medical Biology and Pathology, Gustave Roussy and University Paris Saclay, Villejuif, France.Search for more papers by this author, Livia LamartinaDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.Search for more papers by this author, Martin SchlumbergerDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and University Paris Saclay, Villejuif, France.Search for more papers by this author, Yann GodbertDepartment of Oncology and Department of Nuclear Medicine, CLCC Institut Bergonié, Bordeaux, France.Search for more papers by this author, and Isabelle BorgetDepartment of Epidemiology and Biostatistics, Gustave Roussy and University Paris Saclay, Villejuif, France.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/thy.2023.0240AboutSectionsView articleView Full TextSupplemental MaterialPDF/EPUBView Supplemental Data Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byMERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine-Refractory RAS-Mutated Differentiated Thyroid Cancers Theodora Pappa16 August 2023 | Clinical Thyroidology®, Vol. 35, No. 8 Volume 33Issue 9Sep 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadege Anizan, Aurelie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, and Isabelle Borget.MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer.Thyroid®.Sep 2023.1124-1129.http://doi.org/10.1089/thy.2023.0240Published in Volume: 33 Issue 9: September 13, 2023Online Ahead of Print:July 26, 2023Online Ahead of Editing: June 23, 2023PDF download
Referência(s)